Payment overview · 2025
General Payments
$925.29
42 reported records · 15 companies
Healthcare provider profile · identity verified
Chhatrapal S Thakur, MD
Allopathic & Osteopathic Physicians|Internal Medicine · COCONUT CREEK, FL · NPI 1871578088
Verified facts
What the public records show
CMS Open Payments records show Chhatrapal S Thakur, MD received $925.29 in general payments during 2025 across 42 reported records.
Insmed, Inc. accounted for 22.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Creon by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 355 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 355 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Insmed, Inc. | Unresolved — no canonical attribution shown | $204.62 | 22.1% | 10 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $119.94 | 13.0% | 6 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $101.47 | 11.0% | 5 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $82.39 | 8.9% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $79.44 | 8.6% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $74.67 | 8.1% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $51.87 | 5.6% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $45.21 | 4.9% | 2 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $34.18 | 3.7% | 1 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $31.08 | 3.4% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $28.41 | 3.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $20.00 | 2.2% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $19.01 | 2.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.67 | 1.8% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $16.33 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $925.29 | 42 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $180.50 | 9 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $119.94 | 6 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $101.47 | 5 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $82.39 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $79.44 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $74.67 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $74.67 | 3 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $66.77 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $51.87 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $45.21 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $45.21 | 2 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $34.18 | 1 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $31.08 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $28.41 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $19.01 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.67 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $16.33 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $16.33 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 355 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 48 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
48 | 14 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
355 | 109 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
48 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
57 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
65 | 31 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
355 | 109 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 756 | 203 |
| Amlodipine Besylate | Amlodipine Besylate | 508 | 154 |
| Eliquis | Apixaban | 355 | 109 |
| Metoprolol Tartrate | Metoprolol Tartrate | 286 | 116 |
| Losartan Potassium | Losartan Potassium | 275 | 115 |
| Furosemide | Furosemide | 273 | 109 |
| Pantoprazole Sodium | Pantoprazole Sodium | 270 | 142 |
| Lisinopril | Lisinopril | 260 | 76 |
| Clopidogrel | Clopidogrel Bisulfate | 253 | 91 |
| Tamsulosin Hcl | Tamsulosin Hcl | 239 | 63 |
| Levothyroxine Sodium | Levothyroxine Sodium | 230 | 49 |
| Gabapentin | Gabapentin | 228 | 72 |
| Metformin Hcl | Metformin Hcl | 211 | 59 |
| Carvedilol | Carvedilol | 175 | 77 |
| Quetiapine Fumarate | Quetiapine Fumarate | 168 | 37 |
| Escitalopram Oxalate | Escitalopram Oxalate | 135 | 31 |
| Prednisone | Prednisone | 134 | 120 |
| Mirtazapine | Mirtazapine | 127 | 34 |
| Tradjenta | Linagliptin | 123 | 42 |
| Hydralazine Hcl | Hydralazine Hcl | 122 | 43 |
| Xarelto | Rivaroxaban | 119 | 22 |
| Levetiracetam | Levetiracetam | 115 | 27 |
| Metoprolol Succinate | Metoprolol Succinate | 102 | 62 |
| Donepezil Hcl | Donepezil Hcl | 99 | 17 |
| Finasteride | Finasteride | 99 | 22 |
| Trazodone Hcl | Trazodone Hcl | 99 | 24 |
| Nifedipine Er | Nifedipine | 94 | 47 |
| Doxycycline Hyclate | Doxycycline Hyclate | 91 | 86 |
| Amiodarone Hcl | Amiodarone Hcl | 83 | 33 |
| Januvia | Sitagliptin Phosphate | 82 | suppressed |
| Potassium Chloride | Potassium Chloride | 80 | 27 |
| Bumetanide | Bumetanide | 78 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 75 | 59 |
| Famotidine | Famotidine | 75 | 38 |
| Cefdinir | Cefdinir | 70 | 67 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 68 | 21 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 67 | 24 |
| Labetalol Hcl | Labetalol Hcl | 66 | 11 |
| Entresto | Sacubitril/Valsartan | 65 | 31 |
| Montelukast Sodium | Montelukast Sodium | 65 | 11 |
| Valsartan | Valsartan | 62 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 61 | 55 |
| Divalproex Sodium | Divalproex Sodium | 61 | 13 |
| Sertraline Hcl | Sertraline Hcl | 61 | 20 |
| Azithromycin | Azithromycin | 57 | 50 |
| Trulicity | Dulaglutide | 57 | suppressed |
| Omeprazole | Omeprazole | 56 | 13 |
| Risperidone | Risperidone | 56 | suppressed |
| Allopurinol | Allopurinol | 54 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 53 | 49 |
| Duloxetine Hcl | Duloxetine Hcl | 52 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 50 | 22 |
| Spironolactone | Spironolactone | 50 | 34 |
| Jardiance | Empagliflozin | 48 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 46 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 45 | 15 |
| Memantine Hcl | Memantine Hcl | 45 | suppressed |
| Insulin Lispro | Insulin Lispro | 44 | 15 |
| Tramadol Hcl | Tramadol Hcl | 44 | 27 |
| Doxazosin Mesylate | Doxazosin Mesylate | 42 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 41 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 40 | suppressed |
| Topiramate | Topiramate | 40 | suppressed |
| Aripiprazole | Aripiprazole | 39 | 11 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 39 | 19 |
| Baclofen | Baclofen | 38 | 13 |
| Clonidine Hcl | Clonidine Hcl | 38 | 22 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 38 | suppressed |
| Sucralfate | Sucralfate | 37 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 35 | suppressed |
| Atenolol | Atenolol | 32 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 32 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 29 | 22 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 28 | suppressed |
| Digoxin | Digoxin | 27 | suppressed |
| Latanoprost | Latanoprost | 27 | suppressed |
| Levofloxacin | Levofloxacin | 27 | 26 |
| Benztropine Mesylate | Benztropine Mesylate | 26 | suppressed |
| Lorazepam | Lorazepam | 26 | 14 |
| Ozempic | Semaglutide | 26 | suppressed |
| Travoprost | Travoprost | 26 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 25 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 25 | 17 |
| Methenamine Hippurate | Methenamine Hippurate | 24 | suppressed |
| Scopolamine | Scopolamine | 24 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 23 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 23 | 22 |
| Metformin Hcl Er | Metformin Hcl | 23 | suppressed |
| Sotalol | Sotalol Hcl | 23 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 23 | suppressed |
| Alprazolam | Alprazolam | 22 | suppressed |
| Cephalexin | Cephalexin | 22 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 22 | 17 |
| Ondansetron Hcl | Ondansetron Hcl | 22 | 22 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 22 | 22 |
| Pregabalin | Pregabalin | 22 | 11 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 22 | 22 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 21 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 21 | suppressed |
| Simvastatin | Simvastatin | 21 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Folic Acid | Folic Acid | 19 | suppressed |
| Lamotrigine | Lamotrigine | 19 | suppressed |
| Prezcobix | Darunavir/Cobicistat | 19 | suppressed |
| Celecoxib | Celecoxib | 18 | 15 |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | suppressed |
| Brilinta | Ticagrelor | 17 | 17 |
| Clotrimazole | Clotrimazole | 17 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 17 | 13 |
| Glipizide | Glipizide | 17 | 11 |
| Glipizide Er | Glipizide | 17 | suppressed |
| Lactulose | Lactulose | 17 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 14 |
| Temazepam | Temazepam | 17 | suppressed |
| Ursodiol | Ursodiol | 17 | suppressed |
| Vancomycin Hcl | Vancomycin/Water For Inj (Peg) | 17 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 16 | 16 |
| Fluconazole | Fluconazole | 16 | 15 |
| Glimepiride | Glimepiride | 16 | suppressed |
| Humalog | Insulin Lispro | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | 14 |
| Albuterol Sulfate | Albuterol Sulfate | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | 11 |
| Primidone | Primidone | 15 | suppressed |
| Dexamethasone | Dexamethasone | 14 | 13 |
| Ibuprofen | Ibuprofen | 14 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | 12 |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Ezetimibe | Ezetimibe | 12 | suppressed |
| Isentress | Raltegravir Potassium | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Dorzolamide-Timolol | Dorzolamide/Timolol/Pf | 11 | suppressed |
| Pancreaze | Lipase/Protease/Amylase | 11 | suppressed |
| Repaglinide | Repaglinide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $925.29 · 42 records | Insmed, Inc. | Arikayce, Brinsupri, CAMZYOS, Cologuard Collection Kit, ELIQUIS, FREESTYLE LIBRE 3, INGREZZA, JARDIANCE, Kerendia, LEQVIO, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, Rystiggo, UBRELVY, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error